10x Genomics is trading 11.7% up now at $42.32 as investors continue to react positively to the strategic benefits of its Proteintech Genomics acquisition.
- The acquisition, slated for June 9, 2026, is expected to significantly expand the company's capabilities within the proteomics and multiomics sectors.
- Market participants are bidding up the stock as they digest the long-term advantages for the company's leadership in single-cell and spatial biology.
- The upward momentum persists today despite a lack of new company-specific headlines, suggesting sustained confidence in the deal's value proposition.